Cogent Biosciences, Inc. COGT
Set alert
29.73 USD -1.29 -4.16%
At close · Nov 2
29.73 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
29.70 Day range 31.48
13.78 52-week range 43.73
- YTD
- -16.30%
- 1 year
- +82.39%
- Open
- 31.31
- Prev close
- 31.02
- Mkt cap
- 5.16B
- Vol
- 2.00M
- Avg vol
- 2.00M
- EPS
- -2.16
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 29.70
- High
- 31.48
- Forward P/E
- -24.85
- Beta
- 0.34
- Short ratio
- 8.48
- Inst. own
- 115.65%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 6, 2026
- 50-d avg
- 32.43
- 200-d avg
- 35.71
- 1y target
- 55.82
3M chart
Events in this range
- Aug 10, 2026Earnings: -0.52; estimate -0.55497; surprise 6.3%
- Aug 12, 2026Rating: Guggenheim · Buy → Buy
- Aug 17, 2026Rating: Piper Sandler · Overweight → Overweight
- Sep 15, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Sep 16, 2026Rating: Wedbush · Outperform → Outperform
Signals (18)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 8 hours ago |
| SMA: Bullish | Oct 27, 2026 | 6 days ago |
| SMA: Bearish | Oct 26, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 19, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 7, 2026 | 3 weeks ago |
| MACD: Buy Signal | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 3 months ago |
| SMA: Bearish | Aug 3, 2026 | 3 months ago |
Key statistics
- Market cap
- 5.16B
- Enterprise value
- 4.90B
- Trailing P/E
- 0.00
- Forward P/E
- -24.85
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 10.91
- EPS (TTM)
- -2.16
- Beta
- 0.34
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -186.15M
- Total cash
- 792.30M
- Total debt
- 244.26M
- Return on equity
- -109.74%
- Shares outstanding
- 173.52M
- Short % of float
- 11.39%
- 50-day average
- 32.43
- 200-day average
- 35.71
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 55.82 +87.8% upside
Now 29.73
- Target (low)
- 45.00
- Target (mean)
- 55.82
- Target (high)
- 62.00
Ratings (0m) 12 11 buy · 1 hold · 0 sell
- Strong buy2
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 6, 2026
Expected Nov 6, 2026. Consensus EPS estimate -0.55027.
Financials — quick view
COGT Revenue — quarterly 0
COGT Net income — quarterly -96.41M
COGT EPS — quarterly -0.52
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2026 | Sep 30, 2026 | -0.55726 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.55497 | -0.52 | +0.03 | +6.30% |
| May 5, 2026 | Mar 31, 2026 | -0.53 | -0.53 | 0.00 | 0.00% |
| Feb 17, 2026 | Dec 31, 2025 | -0.51 | -0.55 | -0.04 | -7.84% |
| Nov 7, 2025 | Sep 30, 2025 | -0.54 | -0.50 | +0.04 | +7.41% |
| Aug 5, 2025 | Jun 30, 2025 | -0.55 | -0.53 | +0.02 | +3.64% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 16, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 17, 2026 | Piper Sandler | main | Overweight | Overweight |
| Aug 12, 2026 | Guggenheim | main | Buy | Buy |
| May 29, 2026 | Wedbush | reit | Outperform | Outperform |
| May 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cogentbio.com
News
- Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference
- If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today
- Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years
- $1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today
- Cogent Biosciences, Inc. (NASDAQ:COGT) Stock Has Consensus Price Target of $51.56
- Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years
- Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target
- HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target
- FDA Accepts Cogent Biosciences' NDA For Bezuclastinib In Patients With Advanced Systemic Mastocytosis
- Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Your note
Sign in to keep a note on COGT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FAIRMOUNT FUNDS MANAGEMENT LLC | Director | Sale | Jan 21, 2026 | 0 |
| GREEN JOHN L | Chief Financial Officer | Sale | Dec 25, 2025 | 131,834 |
| KEARNS EVAN D J.D. | Officer | Sale | Dec 25, 2025 | 109,398 |
| MORRIS ARLENE M. | Director | Conversion of Exercise of derivative security | Aug 26, 2026 | 0 |
| PINNOW COLE | Officer | Stock Award(Grant) | Dec 16, 2025 | 216,650 |
| ROBBINS ANDREW R. | Chief Executive Officer | Stock Gift | May 18, 2026 | 657,503 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.80% | 25,681,174 | 763.50M | Jun 29, 2026 |
| Blackrock Inc. | 10.00% | 17,352,646 | 515.89M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.65% | 8,072,411 | 239.99M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.27% | 7,412,330 | 220.37M | Jun 29, 2026 |
| State Street Corporation | 4.01% | 6,964,919 | 207.07M | Jun 29, 2026 |
| Jupiter Topco LLC | 3.82% | 6,624,848 | 196.96M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.97% | 5,156,952 | 153.32M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.49% | 4,316,858 | 128.34M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.25% | 3,900,938 | 115.97M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.15% | 3,724,033 | 110.72M | Jun 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.45% | 2,509,157 | 74.60M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.36% | 2,358,212 | 70.11M | Jun 29, 2026 |